These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 8963785

  • 1. [Immunosuppression and the problems in partial liver transplantation].
    Kawasaki M, Hashikura Y, Matsunami H, Makunouchi M.
    Nihon Rinsho Meneki Gakkai Kaishi; 1995 Dec; 18(6):683. PubMed ID: 8963785
    [No Abstract] [Full Text] [Related]

  • 2. Tacrolimus-induced cholestatic syndrome following pediatric liver transplantation and steroid-resistant graft rejection.
    Ganschow R, Albani J, Grabhorn E, Richter A, Burdelski M.
    Pediatr Transplant; 2006 Mar; 10(2):220-4. PubMed ID: 16573611
    [Abstract] [Full Text] [Related]

  • 3. Buccal vs. nasogastric tube administration of tacrolimus after pediatric liver transplantation.
    Goorhuis JF, Scheenstra R, Peeters PM, Albers MJ.
    Pediatr Transplant; 2006 Feb; 10(1):74-7. PubMed ID: 16499591
    [Abstract] [Full Text] [Related]

  • 4. Primary immunosuppression with tacrolimus after liver transplantation: 12-years follow-up.
    Jonas S, Neuhaus R, Junge G, Klupp J, Theruvat T, Langrehr JM, Settmacher U, Neuhaus P.
    Int Immunopharmacol; 2005 Jan; 5(1):125-8. PubMed ID: 15589470
    [Abstract] [Full Text] [Related]

  • 5. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus.
    McAlister VC, Peltekian KM, Malatjalian DA, Colohan S, MacDonald S, Bitter-Suermann H, MacDonald AS.
    Liver Transpl; 2001 Aug; 7(8):701-8. PubMed ID: 11510015
    [Abstract] [Full Text] [Related]

  • 6. Resolution of oral ulcerations after decreasing the dosage of tacrolimus in a liver transplantation recipient.
    Hernández G, Jiménez C, Arriba L, Moreno E, Lucas M.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Nov; 92(5):526-31. PubMed ID: 11709689
    [Abstract] [Full Text] [Related]

  • 7. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L, Verstuyft C, Furlan V, Durrbach A, Letierce A, Ferlicot S, Taburet AM, Charpentier B, Becquemont L.
    Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
    [Abstract] [Full Text] [Related]

  • 8. [Tacrolimus (FK506): clinical, pharmacological and analytical aspects].
    Brunet M.
    Med Clin (Barc); 1997 Jun 14; 109(3):98-106. PubMed ID: 9289523
    [No Abstract] [Full Text] [Related]

  • 9. CNIs: immediate benefits but storing problems for the future?
    Kiuchi T.
    Transplantation; 2008 Oct 27; 86(8):1026-7. PubMed ID: 18946338
    [Abstract] [Full Text] [Related]

  • 10. Immunosuppression in liver transplantation.
    Post DJ, Douglas DD, Mulligan DC.
    Liver Transpl; 2005 Nov 27; 11(11):1307-14. PubMed ID: 16237688
    [No Abstract] [Full Text] [Related]

  • 11. Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients.
    Tector AJ, Fridell JA, Mangus RS, Shah A, Milgrom M, Kwo P, Chalasani N, Yoo H, Rouch D, Liangpunsakul S, Herring S, Lumeng L.
    Liver Transpl; 2004 Mar 27; 10(3):404-7. PubMed ID: 15004768
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Bradycardia associated with intravenous administration of tacrolimus in a liver transplant recipient.
    Cox TH, Baillie GM, Baliga P.
    Pharmacotherapy; 1997 Mar 27; 17(6):1328-30. PubMed ID: 9399620
    [Abstract] [Full Text] [Related]

  • 15. Failure of immunosuppressive drug levels to predict T-cell reactivity in pediatric transplant patients.
    Sampson VB, Dunn SP, Rymeski B, Malatack J, Rong NH, Flynn L, Krueger LJ.
    J Pediatr Surg; 2008 Jun 27; 43(6):1134-41. PubMed ID: 18558196
    [Abstract] [Full Text] [Related]

  • 16. New-onset diabetes after transplantation--should it be a factor in choosing an immunosuppressant regimen for kidney transplant recipients.
    Chadban S.
    Nephrol Dial Transplant; 2008 Jun 27; 23(6):1816-8. PubMed ID: 18326882
    [No Abstract] [Full Text] [Related]

  • 17. Prolonged survival of composite facial allografts in non-human primates associated with posttransplant lymphoproliferative disorder.
    Barth RN, Nam AJ, Stanwix MG, Kukuruga D, Drachenberg CI, Bluebond-Langner R, Hui-Chou H, Shipley ST, Bartlett ST, Rodriguez ED.
    Transplantation; 2009 Dec 15; 88(11):1242-50. PubMed ID: 19996923
    [Abstract] [Full Text] [Related]

  • 18. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study.
    Rinaldi M, Pellegrini C, Martinelli L, Goggi C, Gavazzi A, Campana C, Arbustini E, Grossi P, Regazzi M, Ippoliti G, Vigano M.
    J Heart Lung Transplant; 1997 Oct 15; 16(10):1001-10. PubMed ID: 9361242
    [Abstract] [Full Text] [Related]

  • 19. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M, Yano I, Yoshimura A, Masuda S, Uesugi M, Hosohata K, Katsura T, Ogura Y, Oike F, Takada Y, Uemoto S, Inui K.
    Pharmacogenet Genomics; 2008 May 15; 18(5):413-23. PubMed ID: 18408564
    [Abstract] [Full Text] [Related]

  • 20. Infections and immunosuppression as specific problems in a HIV + patient transplanted for end-stage alcoholic cirrhosis.
    Ricciardi S, Van Wanzeele F, Troisi R.
    Acta Chir Belg; 2007 May 15; 107(2):215-8. PubMed ID: 17515275
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.